Clinical Trial Update: Neoadjuvant mFOLFOXIRI Plus Bevacizumab in Patients With High-Risk Locally Advanced Rectal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating neoadjuvant therapy with mFOLFOXIRI plus bevacizumab in patients with high-risk locally advanced rectal cancer and is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• MFOLFOXIRI

Snippet

Sponsor: Yanhong Deng | Conditions: Rectal Cancer | Phase 3 | Status: RECRUITING